Research Article
Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Table 3
Effects of liraglutide treatment on clinical characteristics and biochemical and metabolic parameters.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abbreviations: BMI: body mass index; FBG: fasting blood glucose; 2 hPBG: 2-hour postprandial blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; HbA1c: glycated hemoglobin; TC: total cholesterol; HDL: high-density lipoprotein cholesterol; TG: triglyceride; LDL: low-density lipoprotein cholesterol; ALT: alanine amino transferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: γ-glutamyl transferase; FGF21: fibroblast growth factor 21. ; . |